Member Info for B2HS2L

Giz -

NCYT / YGEN have been negotiating since May.

The price NCYT have offered must include this Illumina contract extension.

YGEN directors happy with the NCYT offer.

+++

"novacyt maybe are looking at placing 3 directors from ygen onto board" - is that a guestimate or your research with this comment?

HarC Davand - Read YGEN RNS 13.06.2023. - That's not the case.

YGEN to receive 1 mil US$ in September, the rest later, quite a bit later.

Icecool agreed, - as long as you take the opportunity to invest in this company at this low sp.

Saint -

If Lynn Rees stays longer than a few months, JM will be watching his budget spend like a hawk.

Harchris, in the first half of 2020, we were getting regular updates about who had agreed to make our assays, which countries had approved our tests etc. As soon as we had paid the debt off GM stated something along the lines of 'we are a bigger outfit now and don't need to RNS so much info'. That turned out to be code for 'We shall not be saying anything further outside the regular updates, half and full year reports' etc.

Can't remember that far back Newbee007.

It's possibly referring to their need for further distributors.

https://events.jspargo.com/aacc23/Public/eventmap.aspx?shmode=E&shExhlist=1&ID=100962&sortMenu=104000

The link shows Novacyt will be attending 2023 AACC.

Thanks for sharing your find D-Geeman, I also posted this on Synairgen:

FWIW this is in the text:

https://www.congress.gov/bill/117th-congress/senate-bill/1644/text

"(6) Drugs and biological products granted provisional approval under the pathway established under this Act are limited to a 2-year approval period, renewable every 2 years, for up to 6 years. Full approval can awarded at any time, for any drug or biological product provisionally approved under this pathway that establishes a 15 percent improvement in an important endpoint compared to standard therapies.

(7) The approval pathway established under this Act prohibits denial of coverage for any drug or biological product provisionally approved under this approval pathway on account of it being experimental."

FWIW this is in the text:

https://www.congress.gov/bill/117th-congress/senate-bill/1644/text

"(6) Drugs and biological products granted provisional approval under the pathway established under this Act are limited to a 2-year approval period, renewable every 2 years, for up to 6 years. Full approval can awarded at any time, for any drug or biological product provisionally approved under this pathway that establishes a 15 percent improvement in an important endpoint compared to standard therapies.

(7) The approval pathway established under this Act prohibits denial of coverage for any drug or biological product provisionally approved under this approval pathway on account of it being experimental."

For me Lyn Rees will be staying for a few months to hand the reigns of YGEN to someone that JW selects, then be gone.

He overstretched the finances at YGEN, and is responsible for the companies present state of affairs. That won't be a good enough track record for Wakefield IMO.

Desree - I'd like to re-install Jonathan Tidswell-Pretorius.

I've shouted this from the cloakroom where I'm fetching my coat.

My sorry *rse is leaving the building imminently.

Wilson, - FWIW I get 'This page doesn't exist' when entering this link.

I guess I've been sin binned, or awarded an ASBO🤦‍♂️

Neil, - I can't find Matthew Mayhew's presence on Linkedin, but that's not unusual recently.

I don't know his present job description, but I would imagine it's similar to Vito Cinquepalmi

Wilson, - JW otherwise described as - popular as Pig Sh**. 😒

Hi neilrich, I was hoping your post didn't mean the demise of Thomas Heister.

Here's the difference on Linkedin , and Heister still a NCYT employee.

++++

Thomas Heister

European Sales Manager

Novacyt Group · Full-time

Mar 2022 - Present · 1 yr 5 mos

Bonn, Nordrhein-Westfalen, Deutschland

++++

Madalina Enache

Technical Sales Manager Europe

Page 4 - "NEW! genesig MYPL EX qPCR Kits genesigMYPLEX qPCR Kit STD is a unique pick and mix multiplex qPCR assay which allows simultaneous detection of up to 3 different STD viruses. The innovative genesigMYPLEX format allows you to choose any of the 10 most prevalent STD viruses to be combined in a customised 2 or 3-way qPCR multiplex assay. The genesigMYPLEX format is a brand-new approach to multiplex and any selection can be delivered within 4 weeks."

So the lab technician is selecting the 2 or 3 assays (from 10) that he/she wants to place in one assay, to create a single multiplex test for the most likely STD's from a sample. - Has anyone heard of that selection capability from another multiplex test manufacturer?

I haven't, - but stand to be corrected, - on this potentially market disruptive Multiplex assay development

I think they have bought time.

The next acquisition is at hand.. 💖💖

Https://shop.novacyt.com/

Taking shape here but hope to see it fully populated and operational soon 👌✨✨✨

How about an introductory offer with this?

This is no way to introduce a new product, which deserves much more information, even if by multi-tweet.

EX-

From the CTDA spreadsheet column A header -

'The name and address of the registered place of business of the person who made the application under regulation 38A' - Seems the spreadsheet author was not mistaken, and now we know who makes at least some of our LFT's.

CTDA regulation 38A

https://www.legislation.gov.uk/uksi/2021/910/regulation/6/made

Same webpage: Register of approved coronavirus test devices

38C.—(1) The Secretary of State must establish a register of coronavirus test devices which the Secretary of State has approved in accordance with regulation 38A.

(2) The Secretary of State must publish the register on the http://gov.uk website.

(3) The register must contain the following information in respect of each coronavirus test device—

(a)the name and address of the registered place of business of the person who made the application under regulation 38A;

(b)if the person who made the application was not the manufacturer, the name and address of the registered place of business of the manufacturer;

(c)the country in which the manufacturer is established;

(d)the name and address of the registered place of business of the UK responsible person or the manufacturer’s authorised representative having a registered place of business in Northern Ireland, if there is one in respect of the device

+++++

Alltest made this LFT.

The partner - Alltest, also makes the LFT reader.

Makes sense to have the LFT and reader made by the same company.